Oppenheimer & Co. Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 636,215 shares of the biopharmaceutical company's stock after buying an additional 54,844 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Pfizer were worth $16,122,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Rialto Wealth Management LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the fourth quarter worth $30,000. Institutional investors own 68.36% of the company's stock.
Pfizer Price Performance
NYSE:PFE opened at $23.97 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The business's 50-day moving average price is $23.26 and its 200 day moving average price is $24.89. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The firm has a market cap of $136.27 billion, a P/E ratio of 17.37, a PEG ratio of 0.87 and a beta of 0.57.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 EPS. The business's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.18%. The ex-dividend date was Friday, May 9th. Pfizer's payout ratio is 124.64%.
Analyst Ratings Changes
PFE has been the subject of a number of analyst reports. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.
Get Our Latest Stock Analysis on Pfizer
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
